The fund is nothing more than a rebadging exercise in the hope people might think it is a new policy. And it’s being used to airbrush public hospitals out of the Medicare picture.
Academic rigour, journalistic flair
Articles on PBS
Displaying 21 - 40 of 67 articles
An independent expert provides his pick of the most notable drugs added to the PBS on May 1, 2017.
When the Corporation for Public Broadcasting was founded 50 years ago, it was supposed to reflect the nation’s disparate voices.
As the Trump administration settles into office, regulators and lawmakers have big plans for shifting the country’s media landscape, with potentially profound effects on the public.
A Grattan Institute report released today, Cutting a better drug deal, calls for a major shake-up of pharmacies and pharmaceutical pricing.
Australia is spending more than A$500 million a year too much for pharmaceuticals because of a little known loophole that allows drug companies to overcharge the government.
Health policy was an important factor in the election outcome, but one of the most important issues in the health sector – the impact of out-of-pocket costs – was mostly ignored.
With the presidential debates being derided as evidence we live in a “post-fact” political world, why aren’t the moderators “truth vigilantes”?
If Australia’s new prime minister wishes to lead a successful 21st-century government, he must tackle the rise in chronic disease and use data to constantly improve the system.
Before the last round of negotiations, only a handful of issues remained in the way of concluding the TPP. A potential deal-breaker for Australia was intellectual property protections for biologics.
Most of us would agree that cancer drugs should be listed on the PBS, no matter how dear. But our health system can’t afford all of them. How then are decisions about which drugs to subsidise made?
The off-label use of medicines is not illegal and it doesn’t mean regulators have specifically “disapproved” its use. But there are a number of issues to consider before using a medicine off-label.
We thought the phone hacking scandal would chasten News Corp. We were wrong.
A group of American airmen broke US laws and evaded the FBI to support the nascent country of Israel in 1948. We should consider them heroes. Jonathan Pollard – not so much.
If you want to see how the market failure model works, look across the Atlantic at PBS and NPR and be afraid.
Biologics are widely accepted as the most effective way of treating certain diseases. They have become the fastest-growing class of therapeutic compounds, with about 300 now available for human use.
Hope, fear, and desperation, along with the unique characteristics of the cancer drug market, create a “perfect storm” that continues to drive up prices for cancer drugs.
Despite numerous leaks about impending changes to medicines policy, the budget showed savings of just $252.2 million over five years from adjusting the price of a small number of PBS-listed drugs.
Australians make an average of 14 visits to the pharmacy for medicines and advice every year but most don’t know about the agreement that governs how we buy government-subsidised medicines from them.
Apart from proposing a co-payment for visiting doctors, the last federal budget also contained a proposal to increase the level of co-payments for medications. The government seems to have given little…
Job Board
-
Deputy Social Media Producer
-
Research Fellow /Senior Research Fellow – Implementation Science
-
Associate Professor, Occupational Therapy
-
GRAINS RESEARCH AND DEVELOPMENT CORPORATION CHAIRPERSON
-
Faculty of Law - Academic Appointment Opportunities
Top contributors
-
Honorary Enterprise Professor, School of Population and Global Health, and Department of General Practice and Primary Care, The University of Melbourne
-
Professor of Health Economics, The University of Melbourne
-
ARC Future Fellow, Australian National University
-
Professor of Health Economics, University of Technology Sydney
-
Senior Research Fellow, University of Technology Sydney
-
Professor of Health Economics, The University of Melbourne
-
Research Fellow, Flinders University
-
Dean, University of Wollongong
-
Professor of Journalism, Media and Communication, Queensland University of Technology
-
Associate Professor of the School of Pharmacy, University of Sydney
-
Professor of Health Economics, Flinders University
-
Associate Professor in Public Health, La Trobe University
-
Deputy Director, Burnet Institute, Adjunct Professor, Monash University, Burnet Institute
-
Professor of Health Policy, Curtin University
-
Professor of Health Economics and Director, Centre for Health Economics Research and Evaluation, University of Technology Sydney
